Johnson & Johnson(JNJ)
Drug Manufacturers - General · New Brunswick, NJ
$270.27-4.96 (-1.80%)
Delayed quote: Sep 8, 2026, 2:50 PM EDT
Drug Manufacturers - General · New Brunswick, NJ
Delayed quote: Sep 8, 2026, 2:50 PM EDT
Free cash flow CAGR uses the stored cash-flow statement history.
Over longer horizons, Free Cash Flow CAGR averages 4.53% over 3 years and -2.05% over 5 years; the trailing 12 months came in at +14.00%.The TTM figure compares the trailing 12 months (sum of the latest four quarters) with the 12 months before that. Rows in the history table compare fiscal years, and the quarterly table compares single quarters; the three measure different windows and will differ. Free cash flow CAGR measures how the company's cash generation has grown. FCF represents the cash available for dividends, buybacks, debt reduction, or reinvestment.
Johnson & Johnson (JNJ)
Free Cash Flow growth vs the same quarter one year earlier, last 40 quarters.
Reported quarterly free cash flow; no daily interpolation.
| Year | Start FCF | End FCF | Change | % Change |
|---|---|---|---|---|
| 2025 | $19.84B | $19.70B | −$144.00M | -0.73% |
| 2024 | $18.25B | $19.84B | +$1.59B | +8.74% |
| 2023 | $17.18B | $18.25B | +$1.06B | +6.19% |
| 2022 | $19.76B | $17.18B | −$2.57B | -13.02% |
| 2021 | $20.19B | $19.76B | −$431.00M | -2.13% |
| 2020 | $19.92B | $20.19B | +$271.00M | +1.36% |
| 2019 | $18.53B | $19.92B | +$1.39B | +7.48% |
| 2018 | $17.78B | $18.53B | +$754.00M | +4.24% |
| 2017 | $15.54B | $17.78B | +$2.24B | +14.39% |
| 2016 | $15.82B | $15.54B | −$275.00M | -1.74% |
| 2015 | $14.76B | $15.82B | +$1.06B | +7.18% |
| 2014 | $13.82B | $14.76B | +$938.00M | +6.79% |
| 2013 | $12.46B | $13.82B | +$1.36B | +10.89% |
| 2012 | $11.40B | $12.46B | +$1.06B | +9.27% |
| 2011 | $14.00B | $11.40B | −$2.60B | -18.54% |
| 2010 | $14.21B | $14.00B | −$205.00M | -1.44% |
| 2009 | $11.91B | $14.21B | +$2.30B | +19.32% |
| 2008 | $11.94B | $11.91B | −$33.00M | -0.28% |
| 2007 | $11.51B | $11.94B | +$429.00M | +3.73% |
| 2006 | $9.24B | $11.51B | +$2.27B | +24.50% |
| 2005 | $8.96B | $9.24B | +$289.00M | +3.23% |
| 2004 | $8.33B | $8.96B | +$623.00M | +7.48% |
| 2003 | $6.08B | $8.33B | +$2.26B | +37.12% |
| 2002 | $7.13B | $6.08B | −$1.06B | -14.80% |
| 2001 | $4.92B | $7.13B | +$2.22B | +45.07% |
| 2000 | $3.68B | $4.92B | +$1.24B | +33.69% |
| 1999 | −$55.00M | $3.68B | +$3.73B | N/A |
| 1998 | $2.95B | −$55.00M | −$3.01B | -101.86% |
| 1997 | $2.52B | $2.95B | +$434.00M | +17.24% |
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Quarter ended Jun 2026 | $3.39B | +131.4% | +36.7% |
| Quarter ended Mar 2026 | $1.47B | -73.2% | -56.6% |
| Quarter ended Dec 2025 | $5.47B | -34.7% | +13.1% |
| Quarter ended Sep 2025 | $8.38B | +237.9% | +46.7% |
| Quarter ended Jun 2025 | $2.48B | -26.6% | -46.7% |
| Quarter ended Mar 2025 | $3.38B | -30.2% | +18.6% |
| Quarter ended Dec 2024 | $4.84B | -15.3% | -22.9% |
| Quarter ended Sep 2024 | $5.71B | +22.7% | -12.4% |
| Quarter ended Jun 2024 | $4.66B | +63.4% | +52.3% |
| Quarter ended Mar 2024 | $2.85B | -54.6% | +19.0% |
| Quarter ended Dec 2023 | $6.27B | -3.8% | +66.7% |
| Quarter ended Oct 2023 | $6.52B | +113.3% | +22.3% |
| Quarter ended Jul 2023 | $3.06B | +27.7% | -35.2% |
| Quarter ended Apr 2023 | $2.39B | -36.4% | -29.0% |
| Quarter ended Dec 2022 | $3.76B | -29.4% | -12.8% |
| Quarter ended Oct 2022 | $5.33B | +13.0% | -29.3% |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.